About four years after the case was filed—and against the backdrop of a significantly changed COVID-19 vaccine ...
Transaction is Hopewell’s first commercial license of proprietary lipid nanoparticles (LNPs)Hopewell’s LNPs are the preferred delivery solution ...
In recent years, mRNA in lipid nanoparticles (mRNA–LNPs) has emerged as a promising strategy for treating numerous conditions ...
Under the settlement, Genevant Sciences and Arbutus Biopharma will grant Moderna a non-exclusive license to their lipid nanoparticle technology for mRNA delivery in infectious disease vaccines. If ...
Moderna will pay US$950-million upfront in July, 2026, with an additional US$1.3-billion contingent on the outcome of a separate legal appeal, while not owing royalties for the technology in its ...
Lipid nanoparticles deliver mRNA to insulin-producing beta cells, prompting them to express a protective protein that shields them from autoimmune attack.
Expands Pfizer’s access to lipid nanoparticle (LNP) formulation technology, offering a strong strategic fit with Pfizer’s mRNA strategy Pfizer gains option to license Acuitas’ LNP technology for up to ...
Vaccines and other medicines are often packed in little fat droplets, or lipids. In this form, they are absorbed by cells and release their “cargo” once they are there. The trigger is a change in the ...
Liposoma Technology, a science-driven lipid technology company based in the Netherlands, today announced the continued ...
Moderna has reached a major legal settlement worth up to $2.25 billion with Genevant Sciences and Arbutus Biopharma, ending a long-running patent dispute over the lipid nanoparticle (LNP) technology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results